Drug
TVB-2640 clinical trials
Also written TVB-2640, Denifanstat and ASC40.
- studies test it
- 19
- open now
- 2
- in phase 3
- 6
- first study started
- 2013
Keep track of what changes. Save the TVB-2640 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
19 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 4
Sagimet Biosciences Inc. (9) · Ascletis Pharmaceuticals Co., Ltd. (6) · David E Gerber (1) · The University of Texas Health Science Center at San Antonio (1) · Weill Medical College of Cornell University (1) · Mark Evers (1)
Often tested with
Tested in the same studies.
Resmetirom (1) · Bevacizumab (1) · Itraconazole (1) · Enzalutamide (1)
Studies
Open first, then newest update. How each study uses TVB-2640 is read from its arms, and is right about nine times in ten.
Testing it · 19
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)RecruitingPhase 3Sagimet Biosciences Inc.NCT07863193Written as Denifanstat
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1Weill Medical College of Cornell UniversityNCT05743621Written as TVB-2640
- Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung CarcinomasActive, not recruitingPhase 2David E GerberNCT03808558Written as TVB-2640
- A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult ParticipantsCompletedPhase 1Sagimet Biosciences Inc.NCT07216313Written as Denifanstat
- A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne VulgarisCompletedPhase 3Ascletis Pharmaceuticals Co., Ltd.NCT06248008Written as ASC40
- A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne VulgarisCompletedPhase 3Ascletis Pharmaceuticals Co., Ltd.NCT06192264Written as ASC40
- Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne VulgarisCompletedPhase 2Ascletis Pharmaceuticals Co., Ltd.NCT05104125Written as ASC40 25mg
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 FibrosisWithdrawnPhase 3Sagimet Biosciences Inc.NCT06594523Written as Denifanstat
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASHWithdrawnPhase 3Sagimet Biosciences Inc.NCT06692283Written as denifanstat
- Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)CompletedPhase 2Sagimet Biosciences Inc.NCT04906421Written as TVB-2640
- Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Sagimet Biosciences Inc.NCT03938246Written as TVB-2640 25 mg (US)
- Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBMActive, not recruitingPhase 3Ascletis Pharmaceuticals Co., Ltd.NCT05118776Written as ASC40 tablets
- TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.TerminatedPhase 1Mark EversNCT02980029Written as TVB-2640
- A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedPhase 1Sagimet Biosciences Inc.NCT05835180Written as TVB-2640 - 50 mg
- TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade AstrocytomaCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT03032484Written as TVB-2640
- Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male SubjectsCompletedPhase 1Sagimet Biosciences Inc.NCT05657834Written as [14C]-TVB-2640
- Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy SubjectsCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04843449Written as ASC40
- Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy SubjectsCompletedPhase 1Ascletis Pharmaceuticals Co., Ltd.NCT04352361Written as TVB-2640
- A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid TumorsCompletedPhase 1Sagimet Biosciences Inc.NCT02223247Written as TVB-2640
Given in every arm · 1 — TVB-2640 is usual care beside what is tested
Codes
What other systems call TVB-2640 · ClinicalTrials.gg INT001620
- MeSH (NLM) C000717092TVB-2640One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717092 | TVB-2640 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.